
    
      This is an open-label, randomized, 3x3 partial replicated crossover study to evaluate the
      pharmacokinetics and safety/tolerability. Within each period, randomized subjects will be 2
      dosing regimens with a fixed dose combination of Fimasartan/Linagliptin and co-administration
      of Fimasartan and Linagliptin.
    
  